Roy S. Herbst is an Ensign Professor of Medicine (Medical Oncology), Professor of Pharmacology, and Chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital; and Associate Cancer Center Director for Translational Research at Yale Cancer Center. R&D Highlights: Dr. Herbst is nationally recognized for his leadership and expertise in lung cancer treatment and research. He has led the Phase 1 development of several of the new generation of targeted agents for non-small cell lung cancer (NSCLC) and participated in the registration of pembrolizumab for the treatment of advanced NSCLC.